We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+51.2%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$3.01B
AUM Growth
+$676M
Cap. Flow
-$150M
Cap. Flow %
-4.98%
Top 10 Hldgs %
75.26%
Holding
119
New
16
Increased
18
Reduced
26
Closed
23

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$54.2M
2
SRRK icon
Scholar Rock
SRRK
+$27.3M
3
ARWR icon
Arrowhead Research
ARWR
+$27.2M
4
PRTA icon
Prothena Corp
PRTA
+$19.3M
5
KRRO icon
Korro Bio
KRRO
+$13.8M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$114M
2
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$46.9M
3
IMGN
Immunogen Inc
IMGN
+$24M
4
FOLD
Amicus Therapeutics
FOLD
+$23.1M
5
RVMD icon
Revolution Medicines
RVMD
+$20M

Sector Composition

Rank Sector Weight
1 Healthcare 50.36%
2 Consumer Discretionary 46.45%
3 Technology 0.44%
4 Real Estate 0.13%
5 Communication Services 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGMT icon
51
Sagimet Biosciences
SGMT
$440M
$5.01M 0.17%
924,771
– –
PDD icon
52
Pinduoduo
PDD
$125B
$4.75M 0.16%
+32,500
New +$3.94M
FHTX icon
53
Foghorn Therapeutics
FHTX
$281M
$4.65M 0.15%
720,720
-1,000,000
-58% -$4.31M
GBIO
54
DELISTED
Generation Bio
GBIO
$4.64M 0.15%
281,419
– –
HOOK
55
DELISTED
HOOKIPA Pharma
HOOK
$4.59M 0.15%
566,641
– –
KLRS
56
Kalaris Therapeutics
KLRS
$79.7M
$4.49M 0.15%
286,833
– –
ITOS
57
DELISTED
iTeos Therapeutics
ITOS
$4.38M 0.15%
400,000
– –
REPL icon
58
Replimune Group
REPL
$440M
$4.21M 0.14%
500,000
– –
BEKE icon
59
KE Holdings
BEKE
$17.7B
$4.05M 0.13%
250,000
-25,000
-9% -$387K
OMGA
60
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
$3.98M 0.13%
1,323,530
-1,209,515
-48% -$2.45M
PYPL icon
61
CALL
PayPal
PYPL
$50.3B
$3.56M 0.12%
58,000
+26,000
+81% +$1.49M
GPCR icon
62
Structure Therapeutics
GPCR
$3.4B
$3.53M 0.12%
+86,600
New +$4.96M
TRML
63
DELISTED
Tourmaline Bio
TRML
$2.39M 0.08%
91,426
– –
ACHL
64
DELISTED
Achilles Therapeutics
ACHL
$2M 0.07%
2,255,375
– –
IMA
65
ImageneBio Inc
IMA
$64M
$1.97M 0.07%
83,293
-70,833
-46% -$2.31M
ADAG
66
Adagene
ADAG
$245M
$1.93M 0.06%
1,000,000
– –
AMZN icon
67
Amazon
AMZN
$2.45T
$1.82M 0.06%
12,000
– –
BZ icon
68
Kanzhun
BZ
$7.24B
$1.66M 0.06%
100,000
-120,000
-55% -$1.88M
CRIS icon
69
Curis
CRIS
$9.67M
$1.34M 0.04%
5,250
– –
IRWD icon
70
Ironwood Pharmaceuticals
IRWD
$604M
$1.26M 0.04%
110,532
– –
GOOGL icon
71
Alphabet (Google) Class A
GOOGL
$4.09T
$1.09M 0.04%
7,800
+2,300
+42% +$309K
KRON
72
DELISTED
Kronos Bio
KRON
$1.05M 0.04%
842,954
-700,000
-45% -$775K
ALPN
73
DELISTED
Alpine Immune Sciences Inc
ALPN
$967K 0.03%
50,759
-1,142,271
-96% -$15.9M
MSFT icon
74
Microsoft
MSFT
$2.93T
$940K 0.03%
2,500
-3,000
-55% -$1.07M
DDOG icon
75
Datadog
DDOG
$91.5B
$910K 0.03%
7,500
-4,000
-35% -$412K
1 2
3
4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q4 2023 Portfolio in Review

As of Q4 2023, Artal Group held 119 positions worth $3.01B, up 29% from $2.33B the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Artal Group withdrew a net $150M in Q4 2023, closing 23 positions and reducing 26 holdings. Its most notable exit was Mirati Therapeutics, Inc. Common Stock, an estimated $114M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 50% of assets, down from 54% a quarter earlier, followed by Consumer Discretionary and Technology.

Against the trend, Artal Group opened a new position in argenx worth $44.3M.

  • Artal Group's largest Q4 2023 buy was argenx: 116,388 shares worth $44.3M.
  • Artal Group added most to Scholar Rock in Q4 2023, an estimated $27.3M increase.
  • Artal Group's biggest Q4 2023 reduction was Cerevel Therapeutics Holdings, Inc. Common Stock, cutting an estimated $46.9M.
  • Artal Group fully exited Mirati Therapeutics, Inc. Common Stock in Q4 2023, selling an estimated $114M.
  • Artal Group's ten largest holdings make up 75% of its $3.01B portfolio in Q4 2023.
  • Artal Group opened 16 new positions and closed 23 in Q4 2023.
  • Artal Group's portfolio value rose 29% quarter-over-quarter to $3.01B.

Based on Artal Group's 13F filing for Q4 2023, filed 9 Feb 2024.